What a $45 Billion IPO Lock-In Expiry Means for Markets

A wave of IPO lock-in expiries worth $45 billion is set to hit Indian markets over the next few months, potentially injecting fresh volatility into recently listed stocks, according to a report by Nuvama.

Between January 6 and April 30, 2026, pre-listing shareholder lock-ins will expire for 96 companies, unlocking shares worth an estimated $45 billion. While not all of these shares are expected to be sold—many remain with promoters—the sheer scale of potential supply is enough to keep markets on edge.

Lock-in periods restrict promoters and early investors from selling shares for a fixed time after listing. Once these curbs end, the newly tradable shares increase free float, often triggering short-term price swings as investors reassess supply-demand dynamics.

The near-term calendar is especially crowded. On January 7, lock-ins will open for Meesho (110 million shares, 2% of outstanding equity), Aequs (17 million shares, 2%), and Vidya Wires (9 million shares, 4%). Two days later, Nephrocare Health Services will see 2 million shares (2%) come out of lock-in.

The sequence continues through mid-January, with CORONA Remedies, Wakefit Innovations, Park Medi World, ICICI Prudential AMC, KSH International and Gujarat Kidney & Super Speciality all scheduled for lock-in expiries across multiple dates. In several cases, between 2% and 5% of outstanding shares will become eligible for trading within days of each other.

Nuvama cautioned that while lock-in expiries do not automatically lead to selling, they are closely tracked by market participants because synchronized profit-booking by early investors can create sudden supply pressure and amplify volatility.

For retail investors, these dates matter. Stocks often witness temporary price swings around lock-in expiries, making it crucial to track timelines and assess whether selling pressure is structural or merely a short-lived market reaction.